Skip to main content

MindMaze Therapeutics Holding S.A. (0QKQ.L)

London Stock Exchange Industrials Specialty Business ServicesView data quality →
18.1Poor

ValueMarkers Composite Index

Top 0%#44,708 of 44,707

DCF data not available

Piotroski
0/9
Weak
Beneish
-
Altman
-
DCF Value
-
N/A
ROIC
-
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

MindMaze Therapeutics Holding S.A. (0QKQ.L) — VMCI valuation read

Composite valuation read on 0QKQ.L: VMCI 18/100 against a Industrials sector median of 50. The 32-point below-median print is the headline number for MindMaze Therapeutics Holding S.A., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 0QKQ.L: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 0QKQ.L: 0QKQ.L trades at 23.0x earnings, 28% above the Industrials median of 18.0x; ROIC of 13.0% sits 3.0pp above the Industrials median (10.0%); net debt to EBITDA of -0.3x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Industrials closes the value frame.

0QKQ.L fell 2.2% over the trailing 7 days, with a +2.6% read on a 30-day basis.

MindMaze Therapeutics Holding SA engages in the development of AI-powered neurotherapeutics and pharmacological treatments for brain disorders. It focuses on addressing neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions. The company is headquartered in Geneva, Switzerland.

CEO: Alexandre Capet31 employeesCHwww.mindmazetherapeutics.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0QKQ.L’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.